Harrow's Vevye (cyclosporine ophthalmic solution) 0.1% has won major market access in the 2025 Medicare Part D Prescription Drug Program, according to a company press release. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors including Express Scripts, Cigna, Kaiser Permanente and CVS Caremark. These represent more than 25 million Medicare Part D beneficiaries, the company noted.

VEVYE is a non‑preserved, twice-daily dosed prescription drug indicated to treat the signs and symptoms of dry eye disease. Harrow's chairman and chief executive officer, Mark Baum, said they are “thrilled" to have secured these initial Medicare Part D formulary coverages. "For too long, Medicare beneficiaries have lacked an accessible, effective and highly tolerable dry eye treatment. With 67 million Medicare beneficiaries in the United States, including the 54 million with Medicare Part D prescription coverage, there is a substantial need for the unique clinical benefits that VEVYE offers. The prevalence of DED rises with age, and seniors face an increased risk for this chronic condition, affecting their comfort, vision, and overall quality of life. With this expanded access, we can better serve Medicare beneficiaries by improving their eye health, independence, and quality of life.”

The company also noted that VEVYE has achieved broad coverage across other major insurance programs, including 100% of U.S. Medicaid programs and 60% of commercial insurance coverage.